课题基金 / 基金详情

Prospective Monitoring of Newly Approved Cardiovascular Drugs in Older Adults with Frailty

Prospective Monitoring of Newly Approved Cardiovascular Drugs in Older Adults with Frailty
新批准的心血管药物对虚弱老年人的前瞻性监测
批准号:
10338082
负责人:
Dae Hyun Kim
金额:
$51.75万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2024-01-31

项目摘要

项目成果

Dae Hyun Kim的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 心血管疾病(CVD)影响70%的老年人,仍然是发病率和莫尔的主要原因。 在美国的总体。最近有几种新药被批准用于心血管疾病,但还不够清楚 关于它们在年老体弱患者中的使用、益处和风险。自从在体弱的老年人中进行临床试验以来, 可能是昂贵和不切实际的,迫切需要创新战略,以产生新的证据, 及时服用CVD药物。该应用程序的目标是建立一个近实时的前瞻性 医疗保险数据监测计划,以评估新的心血管疾病药物对老年人的好处。一 前瞻性监测计划旨在通过更新新药的有效性和安全性信号, 当新的医疗保险数据可用时,定期进行分析。调查人员将把一个 新的基于索赔的脆弱指数纳入监测计划,以及时生成疾病特异性证据, 以患者为中心的新药净获益(按虚弱状态)。核心假设是,疾病特异性益处 和净收益取决于患者的虚弱程度。疾病特异性获益将使用 有效性的临床试验终点(例如,CVD事件)和安全性(例如,净利润(净利润) 在家里生活和度过的天数,或“在家时间”。为了开展这项工作,调查人员将分析 2011-2017年批准的6种新CVD药物的医疗保险数据:3种抗凝剂vs华法林治疗房颤,2种 抗血小板药与氯吡格雷治疗动脉粥样硬化性CVD,血管紧张素受体-脑啡肽酶抑制剂与依那普利 收缩性心力衰竭结果的有效性和可重复性将通过一个 医疗保险数据子集到电子健康记录和国家调查,以补充临床信息, 以及在2个大型商业数据库中对医疗保险数据分析进行外部验证。在接下来的四年里, 研究者将完成3个具体目标:1)评价新的CVD药物的时间趋势和预测因子 在2011-2020年期间用于患有CVD的虚弱和非虚弱老年人; 2)确定疾病特异性益处(死亡, 6种新型CVD药物与替代疗法相比的净获益(在家时间); 3)确定可以预测新CVD药物净获益(在家时间)的患者特征, 替代疗法该提案的创新方法,结合了近实时的前瞻性监测, ing,一个基于索赔的虚弱评分,以及以患者为中心的家庭时间结果,提供了一个易于扩展和 新批准药物的有效性和安全性比较研究的可行框架。的影响 这项拟议的研究意义重大,因为从真实世界的医疗保健数据中及时生成的证据可以 使临床医生能够根据患者的虚弱程度和预期的净获益来优化新CVD药物的处方。
英文摘要
PROJECT SUMMARY/ABSTRACT Cardiovascular disease (CVD) affects 70% of older adults and remains the leading cause of morbidity and mor- tality in the United States. Several new drugs have recently been approved for CVD, but not enough is known about their utilization, benefits and risks in frail older patients. Since conducting a clinical trial in frail older adults can be costly and impractical, there is a pressing need for innovative strategies to generate evidence on new CVD drugs in a timely manner. The objective of this application is to establish a near-real-time prospective monitoring program in Medicare data to evaluate the benefit of new CVD drugs for older adults with frailty. A prospective monitoring program seeks to find early effectiveness and safety signals of new drugs by updating the analysis at regular intervals as new Medicare data become available. The investigators will incorporate a novel claims-based frailty index into the monitoring program to generate timely evidence on disease-specific and patient-centered net benefit of new drugs by frailty status. The central hypothesis is that disease-specific benefit and net benefit are determined by a patient's degree of frailty. Disease-specific benefit will be evaluated using clinical trial endpoints of effectiveness (e.g., CVD events) and safety (e.g., bleeding), and net benefit in terms of the number of days alive and spent at home, or “home time”. To conduct this work, the investigators will analyze Medicare data on 6 new CVD drugs approved in 2011-2017: 3 anticoagulants vs warfarin for atrial fibrillation, 2 antiplatelets vs clopidogrel for atherosclerotic CVD, and an angiotensin receptor-neprilysin inhibitor vs enalapril for systolic heart failure. The validity and reproducibility of the results will be enhanced through the linkage of a subset of Medicare data to electronic health records and a national survey to supplement clinical information, and external validation of the Medicare data analysis in 2 large commercial databases. In the next 4 years, the investigators will accomplish 3 specific aims: 1) evaluate the temporal trends and predictors of new CVD drug use in frail and non-frail older adults with CVD over 2011-2020; 2) determine disease-specific benefit (deaths, CVD and safety events) and net benefit (home time) of 6 new CVD drugs compared with alternative therapies; 3) identify patient characteristics that can predict net benefit (home time) with new CVD drugs compared with alternative therapies. This proposal's innovative approach, which combines near-real-time prospective monitor- ing, a claims-based frailty score, and the patient-centered outcome of home time, offers a readily scalable and feasible framework for comparative effectiveness and safety studies of newly approved medications. The impact of the proposed research is significant because timely evidence generated from real-world healthcare data can enable clinicians to optimize prescribing of new CVD drugs based on a patient's frailty and expected net benefit.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.2147/clep.s438013
发表时间: 2024
期刊: Clinical epidemiology
影响因子: 3.9
作者: [Bessette,LilyG, Singer,DanielE, Pawar,Ajinkya, Wong,Vincent, Kim,DaeHyun, Lin,KueiyuJoshua]
通讯作者: Lin,KueiyuJoshua
Mid-Career Mentoring Award For Patient-Oriented Research in Frailty and Health Outcomes
Mid-Career Mentoring Award For Patient-Oriented Research in Frailty and Health Outcomes
Applications of Claims-Based Frailty Index to Advance Evidence for Frailty-Guided Decision-Making
Applications of Claims-Based Frailty Index to Advance Evidence for Frailty-Guided Decision-Making
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: